Tucidinostat

Tucidinostat
Clinical data
Trade names	Epidaza
Identifiers
	IUPAC name N-(2-Amino-5-fluorophenyl)-4-[[[1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]methyl]-benzamide;
CAS Number	1616493-44-7 ;
PubChem CID	9800555;
ChemSpider	7976319;
UNII	87CIC980Y0;
CompTox Dashboard (EPA)	DTXSID701032295 ;
Chemical and physical data
Formula	C22H19FN4O2
Molar mass	390.4 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC1=C(NC(=O)C2=CC=C(CNC(=O)\C=C\C3=CN=CC=C3)C=C2)C=C(F)C=C1;
	InChI InChI=1S/C22H19FN4O2/c23-18-8-9-19(24)20(12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+; Key:WXHHICFWKXDFOW-BJMVGYQFSA-N;

Chidamide (Epidaza) is an HDAC inhibitor (HDI) developed wholly in China.^[1] It was originally known as HBI-8000.^[2]

It is a benzamide HDI) and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10.^[3]

It is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL), and having orphan drug status in Japan.^[2]^{[better source needed]}

As of April 2015^[update] it is only approved in China.^[1]

It shows potential in treating pancreatic cancer.^[4]^[5]^[6]

Is NOT approved for the treatment of pancreatic cancer.

References

^ ^a ^b "China's First Homegrown Pharma". April 2015.
^ ^a ^b [1]
^ HUYA Bioscience International Grants An Exclusive License For HBI-8000 In Japan And Other Asian Countries To Eisai. Feb 2016
^ Qiao, Z (2013-04-26). "Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells". Biochem Biophys Res Commun. 434 (1): 95–101. doi:10.1016/j.bbrc.2013.03.059. PMID 23541946.
^ Guha, Malini (2015-04-01). "HDAC inhibitors still need a home run, despite recent approval". Nature Reviews Drug Discovery. 14: 225–226. doi:10.1038/nrd4583.
^ Wang, Shirley S. (2015-04-02). "A New Cancer Drug, Made in China". The Wall Street Journal. Retrieved 13 April 2015.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.